The United Kingdom has approved lurbinectedin in combination with atezolizumab for the first-line maintenance treatment of adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed following initial chemoimmunotherapy.
The approval adds a new maintenance option for patients who completed induction therapy with atezolizumab, carboplatin, and etoposide and achieved disease control.
Lurbinectedin was developed by PharmaMar, with commercialization agreements established in selected markets.
New Maintenance Option for Extensive-Stage Small Cell Lung Cancer
Small cell lung cancer (SCLC) is an aggressive subtype of lung cancer characterized by rapid tumor growth, early metastatic spread, and a high risk of recurrence. Although immunotherapy-based treatment regimens have improved outcomes for many patients with extensive-stage disease, maintaining long-term disease control remains a major clinical challenge.
The approval of lurbinectedin plus atezolizumab introduces a new maintenance approach designed to extend treatment benefit after initial chemoimmunotherapy.
Approval Supported by Phase 3 IMforte Trial Results
The approval was supported by results from the Phase 3 IMforte trial (NCT05091567). The randomized, multicenter study evaluated lurbinectedin plus atezolizumab versus atezolizumab alone as maintenance therapy in patients with extensive-stage small cell lung cancer who had not progressed after first-line induction therapy with atezolizumab, carboplatin, and etoposide. The combination significantly improved both progression-free survival and overall survival compared with atezolizumab alone.
The study included 660 patients who received first-line induction therapy with atezolizumab, carboplatin, and etoposide. Among patients whose disease had not progressed, 483 participants were randomized to receive maintenance therapy with either lurbinectedin plus atezolizumab (242 patients) or atezolizumab alone (241 patients).
The combination therapy significantly improved investigator-assessed progression-free survival:
- Median progression-free survival: 5.4 months with lurbinectedin plus atezolizumab versus 2.1 months with atezolizumab alone
- Hazard ratio (HR): 0.54, representing a 46% reduction in the risk of disease progression or death compared with atezolizumab alone (p<0.0001)
The regimen also demonstrated an improvement in overall survival:
- Median overall survival: 13.2 months with lurbinectedin plus atezolizumab versus 10.6 months with atezolizumab alon
- Hazard ratio (HR): 0.73, corresponding to a 27% reduction in the risk of death (p=0.017)
The safety profile was consistent with the known characteristics of both therapies. Grade 3–4 adverse events occurred in 38% of patients receiving lurbinectedin plus atezolizumab compared with 22% receiving atezolizumab alone. The most frequently reported severe adverse events in the combination group included hematologic toxicities such as anemia, neutropenia, and thrombocytopenia.
The results of the IMforte trial were published in The Lancet in 2025 (DOI: 10.1016/S0140-6736(25)01011-6).
Mechanism of Action: Combining Tumor-Targeting and Immune Activation
Lurbinectedin is a synthetic compound that targets transcription processes involved in tumor growth. By binding to DNA and inhibiting oncogenic transcription, it can interfere with cancer cell proliferation. The therapy also affects components of the tumor microenvironment, including tumor-associated macrophages that may support tumor progression.
Atezolizumab is an immune checkpoint inhibitor targeting PD-L1. By blocking PD-L1 signaling, it helps restore anti-tumor immune activity and enables T cells to better recognize and attack cancer cells.
The combination brings together two complementary approaches: direct effects on tumor biology and activation of the immune response against cancer.
Expanding Treatment Options in Small Cell Lung Cancer
The UK approval follows regulatory decisions in other regions based on the IMforte trial results, expanding access to the lurbinectedin and atezolizumab combination for patients with extensive-stage SCLC.
Despite recent advances, extensive-stage SCLC remains associated with significant unmet medical needs, and researchers continue to investigate new strategies combining chemotherapy, immunotherapy, and targeted treatments to improve outcomes.
Read further on OncoDaily: Early-Stage NSCLC in 2026: From Treatment Intensification to Precision-Guided Curative Strategies
